Investors Buy Shares of Zoetis (ZTS) on Weakness

Investors bought shares of Zoetis Inc. (NYSE:ZTS) on weakness during trading on Monday. $75.99 million flowed into the stock on the tick-up and $34.69 million flowed out of the stock on the tick-down, for a money net flow of $41.30 million into the stock. Of all companies tracked, Zoetis had the 32nd highest net in-flow for the day. Zoetis traded down ($1.28) for the day and closed at $71.02

ZTS has been the subject of several analyst reports. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a report on Wednesday, November 29th. UBS reissued a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Jefferies Group reissued a “buy” rating on shares of Zoetis in a report on Friday, November 10th. Finally, BMO Capital Markets raised their price target on shares of Zoetis from $65.00 to $70.00 and gave the company a “market perform” rating in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $68.24.

The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $34,607.21, a price-to-earnings ratio of 32.58, a PEG ratio of 2.13 and a beta of 1.06.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS. research analysts predict that Zoetis Inc. will post 2.37 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Thursday, November 9th were paid a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, November 8th. Zoetis’s dividend payout ratio is presently 22.11%.

Institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. lifted its stake in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Zoetis in the third quarter worth $114,000. Harfst & Associates Inc. lifted its stake in Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Zoetis in the second quarter worth $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares during the period. 93.33% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/12/06/investors-buy-shares-of-zoetis-zts-on-weakness.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply